Evidence-based evaluation of recent clinical practice guidelines for the diagnosis and treatment of benign prostatic hyperplasia

目的 循证评价全球良性前列腺增生症临床诊治实践指南的制定情况、主要内容和方法学质量.方法 检索国内外指南发布平台和主要数据库,搜集良性前列腺增生症诊治的指南或共识,使用AGREEⅡ工具评价方法学质量,分析比较各指南推荐内容的异同.结果 共纳入指南15部.AGREEⅡ评分结果显示范围和目的、参与人员、制定的严谨性、清晰性、适用性和编辑的独立性得分分别为72％、38％、30％、58％、16％和40％.各指南的推荐意见基本相同,但在某些领域存在争议.结论 纳入指南整体质量良莠不齐,内容能为研发与完善指南提供有价值的启示.Objective To systematically evaluate the quality of clinical practice guidelines for the diagnosis and treatment of benign prostatic hyperplasia (BPH),and to compare the context of recommendations in order to provide references for clinical application.Methods We searched databases such as the National Guideline Clearinghouse (NGC),Guidelines International Network (GIN),National Institute for Health and Clinical Excellence (NICE),Scottish Intercollegiate Guidelines Network (SIGN) and World Health Organization (WHO),PubMed,Embase,CNKI,VIP,WanFang Data,CBM,and Medlive from their establishment until August 13,2016,to collect evidence-based guidelines and/or consensus on BPH.Method Methodological quality of included guidelines was assessed according to the AGREE Ⅱ instrument,and differences and similarities among recommendations were compared.Results A total of 15 guidelines were included.According to the AGREE H instrument,the score of scope and purpose,stakeholder involvement,rigour of formulate,clarity of presentation,applicability,and editorial independence was 72％,38％,30％,58％,16％,and 40％,respectively.The recommendations of different guidelines were basically similar,only with conflicts in some areas.Conclusions The quality of included guidelines remains to be unified,the context of them can provide valuable implications for development or improvement.“十三五”国家重点研发计划专项基金(项目号:2016YFC0106300)The National Key Research and Development Program of China中国科学引文数据库(CSCD)221683-16879